Astellas Pharma Inc. (TYO:4503)
Japan · Delayed Price · Currency is JPY | Market Cap | 3.79T |
| Revenue (ttm) | 2.01T |
| Net Income (ttm) | 124.87B |
| Shares Out | 1.79B |
| EPS (ttm) | 69.49 |
| PE Ratio | 30.47 |
| Forward PE | 17.81 |
| Dividend | 78.00 (3.70%) |
| Ex-Dividend Date | Mar 30, 2026 |
| Volume | 12,166,400 |
| Average Volume | 8,263,890 |
| Open | 2,113.00 |
| Previous Close | 2,117.00 |
| Day's Range | 2,082.50 - 2,115.50 |
| 52-Week Range | 1,243.50 - 2,143.50 |
| Beta | 0.04 |
| RSI | 77.96 |
| Earnings Date | Feb 3, 2026 |
About Astellas Pharma
Astellas Pharma Inc. manufactures, markets, imports, and exports pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric cancer; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also provides VEOZAH, a treatment for vasomotor symptoms due to menopause; IZERVAY, a treatment for geographic atrophy secondary to age-related macular degeneration; EVRENZO, a treatment for anemia associated with ch... [Read more]
Financial Performance
In 2024, Astellas Pharma's revenue was 1.91 trillion, an increase of 19.25% compared to the previous year's 1.60 trillion. Earnings were 50.75 billion, an increase of 197.72%.
Financial StatementsNews
Astellas Reports Positive Phase 3 EV-304 Results For PADCEV Combo In Muscle-Invasive Bladder Cancer
(RTTNews) - Astellas Pharma Inc. and Pfizer Inc. announced positive topline results from the Phase 3 EV-304 clinical trial (KEYNOTE-B15), evaluating PADCEV (enfortumab vedotin), a Nectin-4 directed an...
Why Is Monte Rosa Stock Trading Higher Today?
Monte Rosa Therapeutics Inc . (NASDAQ: GLUE) shared interim data from an ongoing Phase 1/2 clinical study evaluating MRT-2359 in combination with enzalutamide in heavily pretreated patients with meta...
Autobahn Labs Forms Strategic Partnership with Astellas to Accelerate Academic Discoveries into New Medicines
PALO ALTO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Autobahn Labs (“Autobahn”), a venture studio focused on transforming high-potential academic science into investable drug discovery and development...
Astellas to Present New Clinical Data Across Its Gastrointestinal Cancers Portfolio at 2026 ASCO GI Cancers Symposium
- Data reflect new insights and precision oncology advancements in portfolio and pipeline - - Cohort results from Phase 2 ILUSTRO study evaluating a zolbetuximab triplet combination regimen in first-l...
Astellas To Present New Data on XOSPATA™ (gilteritinib) Across the FLT3m+ AML Disease Continuum at ASH 2025 Annual Meeting
- Presentations include pooled post-hoc analysis of the Phase 3 ADMIRAL and COMMODORE data on post-transplant gilteritinib resumption in relapsed or refractory FLT3m+ AML - - Findings from the Phase 3...
EMA Validates Review Of Astellas' PADCEV And KEYTRUDA Combination In Bladder Cancer
(RTTNews) - Astellas Pharma Inc. (ALPMY, 4503.T) announced that the European Medicines Agency (EMA) has validated for review a Type II variation application for PADCEV (enfortumab vedotin). PADCEV, a ...
Pfizer : FDA Oks PADCEV + Keytruda Combo For Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
(RTTNews) - Pfizer Inc. (PFE) and Astellas Pharma Inc. (ALPMY, 4503.T) announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV (enfortumab vedotin-ejfv), a Nectin-4 directed ant...
Q2 2026 Astellas Pharma Inc Earnings Presentation Transcript
Q2 2026 Astellas Pharma Inc Earnings Presentation Transcript
Full Year 2025 Astellas Pharma Inc Earnings Presentation Transcript
Full Year 2025 Astellas Pharma Inc Earnings Presentation Transcript
Astellas and the Internet's Favorite Grandma, Barbara 'Babs' Costello, Partner to Encourage Others to Get Ahead of Geographic Atrophy (GA)
Babs is sharing her family's history with progressive retinal disease GA, the advanced form of dry age-related macular degeneration (AMD), is a serious condition that may lead to irreversible vision l...
Astellas Pharma Announces Encouraging Data From OPTION-VMS Phase IV Study
(RTTNews) - Astellas Pharma Inc. (ALPMY.PK), Wednesday announced new real-world preliminary data from the OPTION-VMS Phase IV study, a longitudinal, observational study in participants with VMS, also ...
Astellas Presents Preliminary Real-World VEOZAH™ (fezolinetant) Data From OPTION-VMS Phase IV Observational Study
Extensive and growing evidence continues to reinforce fezolinetant as an effective treatment for moderate to severe VMS associated with menopause Preliminary analysis from OPTION-VMS observational stu...
PADCEV™ (enfortumab vedotin-ejfv) Plus KEYTRUDA® (pembrolizumab) sBLA Granted FDA Priority Review for Treatment of Certain Patients with Muscle-Invasive Bladder Cancer
Results from the pivotal EV-303 trial demonstrated that, when used before and after surgery, the combination reduced the risk of recurrence, progression or death by 60% and the risk of death by 50% in...
Astellas Reports Sustained GA Reduction With Long-Term IZERVAY Treatment In GATHER2 Extension Study
(RTTNews) - Astellas Pharma Inc. announced the first results from the open-label extension (OLE) of its Phase 3 GATHER2 study, revealing that monthly treatment with IZERVAY (avacincaptad pegol intravi...
Astellas-Pfizer's combination therapy halves risk of death in bladder cancer patients
Pfizer and Japanese firm Astellas' drug Padcev, combined with Merck's Keytruda, lowered the risk of tumor recurrence, progression or death in patients suffering from a type of bladder cancer, the comp...
Pfizer, Merck And Astellas Have An 'Enormous New Hope' For Bladder Cancer Patients
Pharma titans Merck, Pfizer and Astellas Pharma are delivering an "enormous new hope" for patients with an aggressive form of bladder cancer.
PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer
First and only combination regimen to improve survival when used before and after surgical cystectomy in cisplatin-ineligible patients with muscle-invasive bladder cancer Unprecedented survival result...
AFI Development
Teva Pharmaceutical Industries Astellas Pharma 3000 . AFI Flex . , . , Teva 305 ( 1840 .) , Astellas 150 ( 1000 .) . AFI Development, , . Teva, Astellas.
Astellas to Present First Real-World VEOZAH™ (fezolinetant) Data at 2025 Annual Meeting of The Menopause Society
TOKYO , Oct. 14, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that VEOZAH™ (fezolinetant), its first-in-class, targeted, non-horm...
Astellas to Present New Data on IZERVAY™ (avacincaptad pegol intravitreal solution) in Geographic Atrophy at AAO 2025 Annual Meeting
Presentations include long-term GATHER2 open-label extension data, real-world treatment patterns on safety, and biomarker insights on geographic atrophy disease progression TOKYO , Oct. 8, 2025 /PRNew...
Astellas Announces Top Management Personnel Change
TOKYO , Sept. 29, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the following changes to its Top Management structure, effective O...
PADCEV™ Plus KEYTRUDA™ Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery
PADCEV plus KEYTRUDA is the first and only regimen to improve survival when used before and after standard of care (surgical cystectomy) in cisplatin-ineligible patients with muscle-invasive bladder c...
Astellas Pharma Inc. 2026 Q1 - Results - Earnings Call Presentation
Astellas Announces a Partnership with the "Korea Institute of Startup and Entrepreneurship Development", an Umbrella Organization of the "Ministry of SMEs and Startups", a Korean Government Agency, for the Operation of the "Partnership with Global Companies Program"
- Supporting Korean Startups' Drug Discovery Research and Global Expansion - - First Pharmaceutical Company from Japan to Actively Support the Operation of the Program - TOKYO , July 17, 2025 /PRNewsw...
China hands 3-1/2-year prison sentence to Astellas' Japanese employee, Nikkei says
TOKYO (Reuters) -A Beijing court on Wednesday sentenced a Japanese employee of Astellas Pharma to 3-1/2 years in prison, the Nikkei newspaper reported, citing the Japanese ambassador to China. Chinese...